title: Management of heart failure: a brief review and selected update.
abstract: Despite innovative medications and devices, heart failure (HF) continues to be the leading cause for admission to hospitals in the United States in patients older than 65 years. Many trials have succeeded in improving survival and many have failed. In this article, the authors briefly review the past, describe the present, and speculate about future HF trials.
authors.affiliation: Department of Cardiovascular Medicine, Cleveland Clinic, 9500 Euclid Avenue, Desk F15, Cleveland, OH 44195, USA.
authors.forename: Samuel
authors.initials: S
authors.lastname: Unzek
authors.forename: Gary S
authors.initials: GS
authors.lastname: Francis
mesh_terms: D065092:Antidiuretic Hormone Receptor Antagonists; D001552:Benzazepines / Q000627:therapeutic use; D002316:Cardiotonic Agents / Q000627:therapeutic use; D004232:Diuretics / Q000627:therapeutic use; D006333:Heart Failure / Q000188:drug therapy / Q000628:therapy*; D006440:Hemofiltration; D006801:Humans; D006835:Hydrazones / Q000627:therapeutic use; D020097:Natriuretic Peptide, Brain / Q000627:therapeutic use; D010138:Pacemaker, Artificial; D011724:Pyridazines / Q000627:therapeutic use; D000077464:Simendan; D000077602:Tolvaptan; D014665:Vasodilator Agents / Q000627:therapeutic use
chemical_list: D065092:Antidiuretic Hormone Receptor Antagonists; D001552:Benzazepines; D002316:Cardiotonic Agents; D004232:Diuretics; D006835:Hydrazones; D011724:Pyridazines; D014665:Vasodilator Agents; D020097:Natriuretic Peptide, Brain; D000077602:Tolvaptan; D000077464:Simendan